Efficacy and Safety of Rimegepant 75 Mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial [Corrigendum]

Lipton RB, Thiry A, Morris BA, Croop R. J Pain Res. 2024 Jul 22:17:2431–2441. The authors have advised that Figure 2 on page 2437 is incorrect. The text “150/241 (27.7%)” in the Placebo n/N (Risk) column for the row Freedom from MBS at 2 hours in the Coprimary section should read “150/541 (27.7%)”. The correct Figure 2 is shown below. Figure 2 Forest plot of coprimary and secondary efficacy endpoints for mITT participants.Abbreviations: mITT, modified intent-to-treat; CI, confidence interval; MBS, most bothersome symptom.Notes: Risks were stratified by use of preventive migraine medication using Mantel–Haenszel risk estimation. Secondary efficacy endpoints are listed in the order specified in the endpoint testing hierarchy. aStatistically significant in hierarchical testing, P<0.05. bStatistically significant in hierarchical testing, P<0.005. cStatistically significant in hierarchical testing, P<0.001. dDirection reversed so that positive risk difference favors rimegepant. The authors apologize for this oversight.